Frankfurt – Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. The acquisition further expands Bruker’s multiomics strategy with biocrates metabolomics kits and assays, and related software and research services.
A CMS team led by lead partner Dr Hendrik Hirsch provided Bruker with comprehensive legal advice on the transaction. The success is proof of the smooth work across borders between CMS Germany and CMS Austria.
biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardised metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform combines innovative sample preparation, metabolite identification, and data analysis.
With this acquisition, Bruker expects to enhance its MS-based metabolomics solutions and to support its expansion into multiomics solutions, including instruments, reagents, software, and research services, thereby building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys (CMS was Bruker's legal advisor for both acquisitions).
Press Contact
presse@cms-hs.com
